Structure/function of α-synuclein in health and disease: Rational development of animal models for Parkinson's and related diseases

Journal of Neurochemistry

Volumn 82, Issue 3, 2002, Pages 449-457

  Kahle, Philipp J ^a,b   Haass, Christian ^a   Kretzschmar, Hans A ^b   Neumann, Manuela ^b  

^a Department of Biochemistry   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; DISEASE MODEL; GENE MUTATION; HUMAN; LONG TERMINAL REPEAT; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MACROMOLECULAR SUBSTANCES; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SYNUCLEINS;

ANIMALIA;

EID: 0036326067     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01020.x     Document Type: Review

References (100)

1. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
2. α-synuclein and the Parkinson's disease-related mutant Ala53Thrα-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells
3. Pure autonomic failure in association with human α-synucleinopathy
4. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein
5. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
6. α-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores
7. Impairment of the ubiquitin-proteasome system by protein aggregation
8. Degradation of α-synuclein by proteasome
9. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
10. Residual structure and dynamics in Parkinson's disease-associated mutants of α-synuclein
11. Accumulation of insoluble α-synuclein in dementia with Lewy bodies
12. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
13. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
14. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
15. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct
16. Non-Aβ component of Alzheimer's disease amyloid (NAC) revisited: NAC and α-synuclein are not associated with Aβ amyloid
17. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
18. Conformational properties of α-synuclein in its free and lipid-associated states
19. A Drosophila model of Parkinson's disease
20. α-synuclein is phosphorylated in synucleinopathy lesions
21. Multiple-system atrophy: A new α-synuclein disease?
22. Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology
23. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch
24. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
25. Rat α-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex
26. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro
27. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
28. Neuronal α-synucleionopathy with severe movement disorder in mice expressing A53T human α-synuclein
29. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly
30. The significance of tau and α-synuclein inclusions in neurodegenerative diseases
31. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease
32. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
33. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease
34. β-synuclein inhibits α-synuclein aggregation. A possible role as an anti-parkinsonian factor
35. The ubiquitin system
36. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease
37. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation
38. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
39. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
40. α-synuclein membrane interactions and lipid specificity
41. Physiology and pathophysiology of α-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein
42. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain
43. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model
44. Accumulation of α-synuclein in autonomic nerves in pure autonomic failure
45. Thermal behavior of proteins: Heat-resistant proteins and their heat-induced secondary structural changes
46. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
47. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
48. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
49. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis
50. Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors
51. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice
52. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein
53. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
54. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease
55. The rat brain synucleins; family of proteins transiently associated with neuronal membrane
56. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal
57. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
58. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
59. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter
60. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease
61. Membrane association and protein conformation of α-synuclein in intact neurons
62. Proteasomal function is impaired in substantia nigra in Parkinson's disease
63. Crosslinking of α-synuclein by advanced glycation endproducts - An early pathophysiological step in Lewy body formation?
64. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
65. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation
66. Membrane binding and self association of α-synucleins
67. Both familial Parkinson's disease mutations accelerate α-synuclein' aggregation
68. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein
69. Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis
70. Mutation in the α-synuclein gene identified in families with Parkinson's disease
71. Synucleins are a novel class of substrates for G protein-coupled receptor kinases
72. Neuropathology in mice expressing human α-synuclein
73. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice
74. Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells
75. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
76. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
77. Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies
78. Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14)
79. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
80. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
81. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
82. α-synuclein in Lewy bodies
83. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders
84. α-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome
85. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein
86. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
87. Evidence for a partially folded intermediate in α-synuclein fibril formation
88. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure
89. Pesticides directly accelerate the rate of α-synuclein fibril formation: A possible factor in Parkinson's disease
90. α-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
91. Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease
92. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
93. α-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
94. Widespread occurrence of α-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies
95. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
96. Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42
97. Lewy body variant of Alzheimer's disease: α-synuclein in dystrophic neurites of Aβ plaques
98. Delayed localization of synelfin (synuclein NACP) to presynaptic terminals in cultured rat hippocampal neurons
99. α-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease
100. Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein